Association of serum Ig free light chains with mortality and ESRD among patients with nondialysis-dependent CKD

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 5, 2015, Pages 740-749

  Ritchie, James ^a   Assi, Lakhvir K ^b   Burmeister, Anne ^b   Hoefield, Richard ^a   Cockwell, Paul ^c,d   Kalra, Philip A ^a  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b Binding Site Group Ltd   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; HEMOGLOBIN; IMMUNOGLOBULIN LIGHT CHAIN; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; DISEASE COURSE; END STAGE RENAL DISEASE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TURBIDIMETRY; AGE; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMPLICATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PREDICTIVE VALUE; PROTEINURIA; SURVIVAL RATE; URINE;

AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CREATININE; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHATES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SURVIVAL RATE;

EID: 84929163135     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09660914     Document Type: Article

References (34)

1. Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, Safford MM, Zhang X, Muntner P, Warnock D: Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 305: 1545–1552, 2011
2. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR: Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 20: 1069–1077, 2009
3. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, Jong PE, Coresh J, Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, de Jong PE, Coresh J, El-Nahas M, Eckardt KU, Kasiske BL, Wright J, Appel L, Greene T, Levin A, Djurdjev O, Wheeler DC, Landray MJ, Townend JN, Emberson J, Clark LE, Macleod A, Marks A, Ali T, Fluck N, Prescott G, Smith DH, Weinstein JR, Johnson ES, Thorp ML, Wetzels JF, Blankestijn PJ, van Zuilen AD, Menon V, Sarnak M, Beck G, Kronenberg F, Kollerits B, Froissart M, Stengel B, Metzger M, Remuzzi G, Ruggenenti P, Perna A, Heerspink HJ, Brenner B, de Zeeuw D, Rossing P, Parving HH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T; Chronic Kidney Disease Prognosis Consortium: Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative metaanalysis of kidney disease population cohorts. Kidney Int 79: 1331–1340, 2011
4. Kovesdy CP, Kalantar-Zadeh K: Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease. Nephrology (Carlton) 14: 408–415, 2009
5. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE: Biomarkers in chronic kidney disease: A review. Kidney Int 80: 806–821, 2011
6. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3: 505–521, 2008
7. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative metaanalysis. Lancet 375: 2073–2081, 2010
8. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Inflammation and cardiovascular events in individuals with andwithout chronic kidney disease. Kidney Int 73: 1406–1412, 2008
9. Cohen G: Immunoglobulin light chains in uremia. Kidney Int Suppl 84: S15–S18, 2003
10. Brebner JA, Stockley RA: Polyclonal free light chains: A biomarker of inflammatory disease or treatment target? F1000 Med Rep 5: 4, 2013
11. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P: Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 3: 1684–1690, 2008
12. Anandram S, Assi LK, Lovatt T, Parkes J, Taylor J, Macwhannell A, Jacob A, Handa S, Harding S, Basu S: Elevated, combined serum free light chain levels and increased mortality: A 5-year followup, UK study. J Clin Pathol 65: 1036–1042, 2012
13. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Therneau TM, Colby CL, Clark RJ, Mead GP, Kumar S, Melton LJ, Rajkumar SV: Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population.Mayo Clin Proc 87: 517–523, 2012
14. Haynes R, Hutchison CA, Emberson J, Dasgupta T, Wheeler DC, Townend JN, Landray MJ, Cockwell P: Serum free light chains and the risk of ESRD and death in CKD. Clin J Am Soc Nephrol 6: 2829–2837, 2011
15. Desjardins L, Liabeuf S, Lenglet A, Lemke H-D, Vanholder R, Choukroun G, Massy ZA; European Uremic Toxin (EUTox)Work Group: Association between free light chain levels, and disease progression and mortality in chronic kidney disease. Toxins (Basel) 5: 2058–2073, 2013
16. Hutchison CA, Burmeister A, Harding SJ, Basnayake K, Church H, Jesky MD, White K, Green CE, Stringer SJ, Bassett P, Ferro CJ, Cockwell P: Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease. Mayo Clin Proc 89: 615–622, 2014
17. Hoefield RA, Kalra PA, Baker P, Lane B, New JP, O’Donoghue DJ, Foley RN, Middleton RJ: Factors associated with kidney disease progression and mortality in a referred CKD population. Am J Kidney Dis 56: 1072–1081, 2010
18. Ritchie J, Rainone F, Green D, Alderson H, Chiu D, Middleton R, O’Donoghue D, Kalra PA: Extreme elevations in blood pressure and all-cause mortality in a referred CKD population: Results from the CRISIS Study. Int J Hypertens 2013: 597906, 2013
19. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39[Suppl 1]: S1–S266, 2002
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461–470, 1999
21. National Institute forHealth and Care Excellence: CG73 Chronic Kidney Disease NICE Guideline, National Institute for Health and Care Excellence, London, 2008, pp 1–36
22. Gilg J, Rao A, Fogarty D:UKRenalRegistry 15thAnnualReport, The Renal Association UK Renal Registry, Bristol, UK 2013, pp 7–34
23. Campbell MJ, Swinscow TDV: Statistics at Square One, 11th Ed., Chichester, UK, Wiley, 2009
24. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ: Prevalence ofmonoclonal gammopathy of undetermined significance. N Engl J Med 354: 1362–1369, 2006
25. Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, Rajkumar SV, Dispenzieri A: Screening panels for detection of monoclonal gammopathies. Clin Chem 55: 1517–1522, 2009
26. Hutchison CA, Basnayake K, Cockwell P: Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol 5: 621–628, 2009
27. Basnayake K, Stringer SJS, Hutchison CAC, Cockwell P: The biology of immunoglobulin free light chains and kidney injury. Kidney Int 79: 1289–1301, 2011
28. Burmeister A, Assi LK, Ferro CJ, Hughes RG, Barnett AH, Bellary S, Cockwell P, Pratt G, Hutchison CA: The relationship between high-sensitivity CRP and polyclonal free light chains as markers of inflammation in chronic disease. Int J Lab Hematol 36: 415–424, 2014
29. Romao JE., Haiashi AR, Elias RM, Luders C, Ferraboli R, Castro MCM, Abensur H: Positive acute-phase inflammatory markers in different stages of chronic kidney disease. Am J Nephrol 26: 59–66, 2006
30. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 17: 2034–2047, 2006
31. Drawz PE, Goswami P, Azem R, Babineau DC, Rahman M: A simple tool to predict end-stage renal disease within 1 year in elderly adults with advanced chronic kidney disease. J Am Geriatr Soc 61: 762–768, 2013
32. Tangri N, Kitsios GD, Inker LA, Griffith J, Naimark DM, Walker S, Rigatto C, Uhlig K, Kent DM, Levey AS: Risk prediction models for patients with chronic kidney disease: A systematic review. Ann Intern Med 158: 596–603, 2013
33. Rijnierse A, Redegeld FAF, Blokhuis BRB, Van der Heijden MWM, Te Velde AA, Pronk I, Hommes DWD, Nijkamp FPF, Koster ASA, Kraneveld ADA: Ig-free light chains play a crucial role in murine mast cell-dependent colitis and are associated with human inflammatory bowel diseases. J Immunol 185: 653–659, 2010
34. Braber S, Thio M, Blokhuis BR, Henricks PAJ, Koelink PJ, Groot Kormelink T, Bezemer GFG, Kerstjens HAM, Postma DS, Garssen J, Kraneveld AD, Redegeld FA, Folkerts G: An association between neutrophils and immunoglobulin free light chains in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 185: 817–824, 2012